Exelixis (EXEL) AI Stock Analysis

• Market Cap: $12.47B
• Dividend Yield: N/A
• Average Volume (3M): 3.69M
• Price to Earnings (P/E): 20.7
• Beta (1Y): 0.67
• Revenue Growth: 24.49%
• EPS Growth: 244.87%
• Country: US
• Employees: 1,147
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): 0.62
• Shares Outstanding: 272,708,280
• 10 Day Avg. Volume: 3,510,178
• 30 Day Avg. Volume: 3,694,405
• PEG Ratio: 0.70
• Price to Book (P/B): 5.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.54
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 1.29
• Enterprise Value/Gross Profit: 4.95
• Enterprise Value/Ebitda: 4.19
• 1Y Price Target: $44.88
• Price Target Upside: 3.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 18

• Rating: 84 Outperform
• Price Target: $51.00 ▲(17.16%Upside)

Exelixis's strong financial performance, positive earnings outlook, and strategic pipeline developments drive its high stock score. The technical indicators support mild bullish sentiment, while the valuation suggests fair pricing. The company's robust cash position and strategic initiatives provide a solid foundation for future growth.

Positive Factors

Market Exclusivity

Challenges to Cabo's IP were ruled in favor of EXEL to retain market exclusivity.

Regulatory Approval

Increased probability-of-success for zanzalintib (Zanza) FDA approval.

Trial Results

EXEL announced positive topline results from the STELLAR-303 Phase 3 pivotal trial for zanzalintinib + atezolizumab versus regorafenib in metastatic colorectal cancer.

Negative Factors

Commercial Risks

Risks include, but are not limited to: commercial risk with respect to Cabometyx (cabozantinib); failure to generate favorable data from ongoing clinical programs, particularly those involving zanzalintinib.

Regulatory Concerns

Questions remain whether the revision could be a regulatory issue for the FDA, given the proximity between when the primary endpoint was changed and the topline release.

Exelixis Business Overview & Revenue Model

Company Description

Exelixis, Inc. is a biotechnology company focused on discovering, developing, and commercializing new medicines to enhance care and outcomes for patients with cancer. Operating primarily in the biopharmaceutical sector, Exelixis is best known for its flagship product, CABOMETYX (cabozantinib), a medication used in the treatment of various forms of cancer, including renal cell carcinoma and hepatocellular carcinoma. The company continues to engage in research and development activities to expand its portfolio of oncology therapies.

How the Company Makes Money

Exelixis primarily generates revenue through the sale of its proprietary cancer treatments, notably CABOMETYX. The company earns money by marketing and distributing these drugs both directly and through strategic partnerships with pharmaceutical companies. A significant portion of its revenue is derived from product sales within the United States, while international sales further contribute to its financial performance. Exelixis also benefits financially from collaborations with other organizations, receiving milestone payments, royalties, and licensing fees. These partnerships help expand the reach of its products and support ongoing research and development efforts to bring new therapies to market.

Exelixis Financial Statement Overview

Summary

Exelixis exhibits strong financial health, with robust revenue growth and profitability margins. The balance sheet is solid, though a slight decline in stockholders' equity requires monitoring. Cash flow is particularly strong, supporting financial flexibility.

Income Statement

Exelixis demonstrates strong revenue growth, with a TTM revenue increase of 6% over the previous year. The company maintains high gross and net profit margins at 96.8% and 28.0% respectively for TTM, reflecting efficient cost management. Additionally, the EBIT and EBITDA margins are robust at 33.1% and 36.7%, indicating solid operational performance.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio of 0.09, suggesting conservative leverage levels. The equity ratio is a healthy 75.1%, showcasing a solid financial foundation. However, stockholders' equity has seen a slight decline over the past year, necessitating monitoring.

Cash Flow

Operating cash flow is robust, with a TTM to net income ratio of 1.31, indicating effective cash generation relative to earnings. Free cash flow has grown significantly by 28.3% from the previous period, supporting financial flexibility and potential reinvestment.

Breakdown	TTM	Mar 2025	Dec 2023	Dec 2022	Dec 2021	Mar 2021
Income Statement
Total Revenue	2.30B	2.17B	1.83B	1.61B	1.43B	987.54M
Gross Profit	2.22B	2.09B	1.76B	1.55B	1.38B	951.27M
EBITDA	844.28M	718.75M	196.60M	222.36M	300.30M	110.06M
Net Income	643.57M	521.27M	207.76M	182.28M	231.06M	111.78M
Balance Sheet
Total Assets	2.84B	2.95B	2.94B	3.07B	2.62B	2.14B
Cash, Cash Equivalents and Short-Term Investments	1.03B	1.11B	995.30M	1.31B	1.47B	1.21B
Total Debt	187.13M	190.82M	189.94M	190.17M	51.27M	49.09M
Total Liabilities	706.22M	703.49M	678.45M	583.06M	405.62M	258.22M
Stockholders Equity	2.13B	2.24B	2.26B	2.49B	2.21B	1.88B
Cash Flow
Free Cash Flow	812.84M	633.79M	170.35M	224.16M	336.58M	178.64M
Operating Cash Flow	842.59M	699.97M	333.32M	362.61M	400.80M	208.98M
Investing Cash Flow	-178.81M	-116.78M	-26.95M	-524.41M	-42.88M	-131.22M
Financing Cash Flow	-739.58M	-628.81M	-546.05M	586.00K	-14.80M	-25.13M

Exelixis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXEL, the sentiment is Positive. The current price of 43.53 is above the 20-day moving average (MA) of 42.41, above the 50-day MA of 40.57, and above the 200-day MA of 35.05, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 56.27 is Neutral, neither overbought nor oversold. The STOCH value of 44.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EXEL.

Exelixis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	84 Outperform	$12.47B	20.74	30.22%	―	24.49%	244.87%
HALO	76 Outperform	$6.64B	14.30	147.06%	―	25.65%	57.10%
INCY	74 Outperform	$13.08B	209.00	0.47%	―	17.13%	-88.78%
CORT	72 Outperform	$7.85B	64.22	21.52%	―	30.93%	11.78%
BMRN	71 Outperform	$10.37B	20.29	9.64%	―	17.99%	152.10%
Sector *	64 Neutral	¥346.04B	10.53	-2.88%	2.72%	11.67%	-7.08%
ASND	52 Neutral	$10.61B	―	357.68%	―	10.69%	34.71%

Exelixis Corporate Events

Exelixis Holds Annual Meeting, Elects New Directors

On May 28, 2025, Exelixis held its Annual Meeting via live webcast, where stockholders elected 11 directors to serve until the next annual meeting in 2026. Additionally, stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 2, 2026, and approved the executive compensation proposal.

The most recent analyst rating on (EXEL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Exelixis stock, see the EXEL Stock Forecast page.

Exelixis Launches Special Equity Award Program

On March 28, 2025, Exelixis, Inc.’s Board of Directors approved a Special Equity Award Program designed to incentivize long-term performance and employee retention over a five-year period. The program offers performance-based restricted stock units to all employees, including executives, with vesting contingent on the company’s stock price reaching specific targets and continued employment, aligning employee interests with shareholder value.